ISIN | LU0695504364 |
---|---|
Valor Number | 14142705 |
Bloomberg Global ID | |
Fund Name | BZ Fine Pharma |
Fund Provider |
BZ Bank Aktiengesellschaft
Wilen, Switzerland Phone: +41 44 786 66 00 Web: www.bzbank.ch |
Fund Provider | BZ Bank Aktiengesellschaft |
Representative in Switzerland |
IPConcept (Schweiz) AG Zürich Phone: +41 044 224 32 09 |
Distributor(s) |
BZ Bank Aktiengesellschaft Wilen b. Wollerau Phone: +41 44 786 61 11 |
Asset Class | Equities |
EFC Category | Equity Health Care |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund does not charge any issuing commission and/or fees (units are issued at the NAV) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | The objective of the investment policy for the fund is to achieve appropriate growth in the respective unit class currency taking account of the investment risk. The total yield of the sub-fund must not only contain the whole of the invested capital but must also be at least equal to inflation and produce an attractive actual yield. The yield should considerably exceed that of fixed-interest and real estate investments. |
Peculiarities |
Current Price * | 207.80 CHF | 11.08.2025 |
---|---|---|
Previous Price * | 207.68 CHF | 08.08.2025 |
52 Week High * | 262.13 CHF | 03.09.2024 |
52 Week Low * | 201.85 CHF | 22.04.2025 |
NAV * | 207.80 CHF | 11.08.2025 |
Issue Price * | 211.96 CHF | 11.08.2025 |
Redemption Price * | 203.64 CHF | 11.08.2025 |
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 23,279,509 | |
Unit/Share Assets *** | 8,467,918 | |
Trading Information SIX |
YTD Performance | -12.21% |
30.12.2024 - 11.08.2025
30.12.2024 11.08.2025 |
---|---|---|
1 month | -2.26% |
11.07.2025 - 11.08.2025
11.07.2025 11.08.2025 |
3 months | +0.99% |
12.05.2025 - 11.08.2025
12.05.2025 11.08.2025 |
6 months | -16.16% |
11.02.2025 - 11.08.2025
11.02.2025 11.08.2025 |
1 year | -17.71% |
12.08.2024 - 11.08.2025
12.08.2024 11.08.2025 |
2 years | -9.82% |
11.08.2023 - 11.08.2025
11.08.2023 11.08.2025 |
3 years | -16.24% |
11.08.2022 - 11.08.2025
11.08.2022 11.08.2025 |
5 years | -23.53% |
11.08.2020 - 11.08.2025
11.08.2020 11.08.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
McKesson Corp | 6.19% | |
---|---|---|
Roche Holding AG | 5.82% | |
Novartis AG Registered Shares | 5.56% | |
AstraZeneca PLC | 5.23% | |
Vertex Pharmaceuticals Inc | 5.18% | |
AbbVie Inc | 4.86% | |
Eli Lilly and Co | 4.69% | |
Alnylam Pharmaceuticals Inc | 4.59% | |
Johnson & Johnson | 4.33% | |
Swedish Orphan Biovitrum AB | 4.27% | |
Last data update | 30.06.2025 |
TER | |
---|---|
TER date | |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.50% |
Ongoing Charges *** | 1.58% |
SRRI ***
|
|
SRRI date *** | 31.07.2025 |